GlobeNewswire·Sep 21, 2026, 4:30 PM ET

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference

Cadrenal Therapeutics CEO Quang X. Pham will participate in the Lytham Partners Fall 2026 Investor Conference webcast on September 29, 2026, at 10:15 a.m. ET.
One-on-one virtual meetings with management are available throughout the conference dates of September 29-30, 2026.
Cadrenal's pipeline includes CAD-1005, a 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT) that holds FDA Orphan Drug Designation, Fast Track status, European Medicines Agency orphan designation, FDA Fast Track for Kawasaki disease, 12-LOX inhibitor CAD-1005 is being developed alongside existing standards of care.
Tecarfarin is a late-stage oral vitamin K antagonist for chronic anticoagulation in conditions such as end-stage kidney disease, atrial fibrillation, left ventricular assist devices, Kawasaki disease, Tecarfarin has received FDA Orphan Drug Designation, Fast Track status, and a request for Rare Pediatric Disease Designation for preventing blood clots in children with Kawasaki disease.
A second-generation 12-LOX oral therapeutic (CAD-2000) is also in development for chronic indications.